Detecting EGFR T790M Mutations From Circulating Tumor Cells

Study Description

The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.

Study Details

Registry ID:

NCT01734915

Conditions:

Non Small Cell Lung Cancer

Phase:

Target Enrollment:

40 participants

Start Date:

November 1, 2012

Healthy Volunteers:

No

Study Locations (4 sites)

• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• Dana-Farber Cancer Institute
  Boston, MassachusettsUnited States, United States
• Memorial Sloan Kettering Cancer Center
  New York, New YorkUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →